301 related articles for article (PubMed ID: 23890595)
1. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
Mallikaarjun S; Kane JM; Bricmont P; McQuade R; Carson W; Sanchez R; Forbes RA; Fleischhacker WW
Schizophr Res; 2013 Oct; 150(1):281-8. PubMed ID: 23890595
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.
Raoufinia A; Peters-Strickland T; Nylander AG; Baker RA; Eramo A; Jin N; Bricmont P; Repella J; McQuade RD; Hertel P; Larsen F
Int J Neuropsychopharmacol; 2017 Apr; 20(4):295-304. PubMed ID: 28204607
[TBL] [Abstract][Full Text] [Related]
4. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.
Fleischhacker WW; Baker RA; Eramo A; Sanchez R; Tsai LF; Peters-Strickland T; Perry PP; McQuade RD; Johnson BR; Carson WH; Kane JM
Schizophr Res; 2014 Nov; 159(2-3):415-20. PubMed ID: 25281992
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y
Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
Harlin M; Yildirim M; Such P; Madera-McDonough J; Jan M; Jin N; Watkin S; Larsen F
CNS Drugs; 2023 Apr; 37(4):337-350. PubMed ID: 36961650
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study.
Findling RL; Kauffman RE; Sallee FR; Carson WH; Nyilas M; Mallikaarjun S; Shoaf SE; Forbes RA; Boulton DW; Pikalov A
J Clin Psychopharmacol; 2008 Aug; 28(4):441-6. PubMed ID: 18626272
[TBL] [Abstract][Full Text] [Related]
8. Initiation of aripiprazole once-monthly in patients with schizophrenia.
Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA
Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956
[TBL] [Abstract][Full Text] [Related]
10. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
[TBL] [Abstract][Full Text] [Related]
11. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
Fleischhacker WW; Sanchez R; Johnson B; Jin N; Forbes RA; McQuade R; Baker RA; Carson W; Kane JM
Int Clin Psychopharmacol; 2013 Jul; 28(4):171-6. PubMed ID: 23615694
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of aripiprazole and concomitant carbamazepine.
Citrome L; Macher JP; Salazar DE; Mallikaarjun S; Boulton DW
J Clin Psychopharmacol; 2007 Jun; 27(3):279-83. PubMed ID: 17502775
[TBL] [Abstract][Full Text] [Related]
14. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
15. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
Gründer G; Fellows C; Janouschek H; Veselinovic T; Boy C; Bröcheler A; Kirschbaum KM; Hellmann S; Spreckelmeyer KM; Hiemke C; Rösch F; Schaefer WM; Vernaleken I
Am J Psychiatry; 2008 Aug; 165(8):988-95. PubMed ID: 18381901
[TBL] [Abstract][Full Text] [Related]
16. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG;
Psychopharmacology (Berl); 2003 Apr; 166(4):391-9. PubMed ID: 12610718
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.
Findling RL; Kauffman R; Sallee FR; Salazar DE; Sahasrabudhe V; Kollia G; Kornhauser DM; Vachharajani NN; Assuncao-Talbott S; Mallikaarjun S; Iwamoto T; McQuade RD; Boulton DW; Blumer J
J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):431-9. PubMed ID: 19702495
[TBL] [Abstract][Full Text] [Related]
19. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
[TBL] [Abstract][Full Text] [Related]
20. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.
Kane JM; Sanchez R; Zhao J; Duca AR; Johnson BR; McQuade RD; Eramo A; Baker RA; Peters-Strickland T
J Med Econ; 2013 Jul; 16(7):917-25. PubMed ID: 23663091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
